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Background: Primary hyperparathyroidism (pHPT) is associated with an increased risk of 
developing breast cancer, but little is known about the underlying factors. The aim of this study 
was to compare women with a history of pHPT and a reference population in terms of standard 
factors predictive of prognosis and response to therapy for breast cancer.
Methods: We analyzed data collected from the National Swedish Cancer Register and from 
two regional oncologic center registries. Seventy-one women with breast cancer and a history of 
parathyroid adenomectomy were compared with 338 matched controls with breast cancer only. 
Tumor size, stage, hormone receptor status, lymph node status, cause of death, and cumulative 
survival were analyzed.
Results: The mean age was 69 ± 11 years (95% confidence interval [CI]: 68–70) in both groups 
and the mean time interval between the parathyroid surgery and breast cancer diagnosis was 
91 ± 68 months (95% CI: 72–111). There were no differences between the two groups regarding 
size, stage, lymph node metastases, or survival, but none of the cases with a history of pHPT 
were found in Stage III or IV .
Conclusion: In conclusion, factors predictive of prognosis and response to therapy in women 
with a history of pHPT and breast cancer are similar to those in breast cancer patients without 
pHPT.
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Introduction
Primary hyperparathyroidism (pHPT) is associated with an increased risk of 
premature death in malignant disorders.1–3 The prevalence of pHPT is highest in 
postmenopausal women, ie, 3%–4%, and the origin is most often a single parathyroid 
adenoma.4,5 Certain malignant tumors are over-represented, and breast cancer is the 
most frequent, comprising 25% of the malignancies diagnosed after parathyroid 
adenomectomy in women.3,6 An increased frequency of parathyroid adenoma and 
significantly higher serum calcium and parathyroid hormone levels have been 
documented in patients treated for breast cancer compared with healthy controls.7 
These findings were unrelated to clinical staging or antitumor therapy. Little is 
known about the association between pHPT and the development of breast cancer. 
Causal relationships have been discussed, and various shared predisposing genetic 
and environmental risk factors have been hypothesized. The aim of this study was to 
evaluate factors predictive of prognosis and response to therapy in a cohort of breast 
cancer patients with a history of pHPT and to search for a potential link between 
pHPT and breast cancer.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Patients and methods
We used the National Swedish Cancer Register to select the 
study population. It is a well-validated register, where under-
reporting is 3%–4%.8 All malignant and a few benign tumors, 
including parathyroid adenomas, are reported to the register 
by both the treating physician and the pathologist making the 
diagnosis. The diagnoses are coded using the International 
Classification of Diseases 7th revision (ICD-7). Requisites for 
inclusion of cases in this study were parathyroid adenomectomy 
of a single parathyroid adenoma (ICD-7 1951) and a subsequent 
diagnosis of invasive breast cancer (ICD-7 170). To minimize 
confounding by diagnosis, we excluded all cases with a breast 
cancer diagnosis before primary hyperparathyroidism (n = 59). 
All males were excluded, as were all women with a diagnosis 
of breast carcinoma in situ.
We identified 71 women with breast cancer and previous 
surgery for pHPT during the period from January 1, 1992 to 
December 31, 2006. For each patient, five control subjects 
with breast cancer but no history of parathyroid surgery, 
matched for age and time period, were enrolled. Using the 
national registration number, a unique identifier for each 
Swedish resident made linkage possible to two of Sweden’s 
six regional breast cancer registers. The registers for the 
Stockholm-Gotland and Uppsala-Örebro regions cover a 
population of 3.9 million, or 43% of the Swedish population. 
Data on tumor size, stage, and hormonal receptor status 
were retrieved. The American Joint Committee on Cancer 
staging system for breast cancer was used.9 Dates of death 
until December 31, 2009 and causes of death until December 
31, 2008 were retrieved from the Swedish Cause of Death 
Register. The study was approved by the ethical committee 
at the Karolinska Institutet, Stockholm, Sweden.
statistical analysis
Statistical analysis was performed with the PASW for 
Windows statistical package (18.0;PASW Inc., Chicago, IL). 
The Student’s two-tailed, unpaired t-test was used to compare 
mean tumor size between the cases and control subjects. 
The Chi-square test was used to compare lymph node 
involvement, and receptor status. The distributions of tumor 
characteristics of cases and controls were compared by 
Pearson Chi-Square test. When cells had expected counts 
less than 5, a corresponding exact test was applied. Survival 
time was calculated as the number of months between the 
date of diagnosis and date of death, or date at end of follow-up 
(whichever occurred first). Breast cancer survival is presented 
in a Kaplan–Meier plot and tested with the logrank test. 
P , 0.05 was considered to be statistically significant.
Results
The mean age at diagnosis of breast cancer was 69 years, with 
a standard deviation (SD) of 11 years (95% confidence interval 
[CI]: 68–70) in both groups. The age distribution for the cases 
and controls is presented in Table 1. The interval between the 
parathyroid adenoma operation and breast cancer registration 
ranged from 1 to 292 months (mean 91 months, SD 68 months, 
95% CI: 72–111). Tumor size, stage, axillary lymph node status, 
and hormone receptor status are presented in Table 2. None of 
the prognostic factors analyzed in this study differed between the 
women with and those without a history of pHPT. The duration 
of follow-up ranged from 0 to 307 months (mean 80 months, 
SD 59 months, 95% CI: 74–86). In December 31, 2009, 29 
(41%) cases and 150 (44%) controls had died. There was no 
statistically significant difference between the two groups in 
cumulative breast cancer-specific survival (see Figure 1).
Discussion
The mechanisms underlying the coexistence of pHPT and 
certain malignancies, including breast cancer, are still 
unknown. To our knowledge, the prognosis of breast cancer 
in women with a history of pHPT has not been studied 
systematically. The aim of our study was to investigate 
whether the prognosis for breast cancer associated with 
pHPT differs from that for breast cancer in the background 
population. Comparing tumor size, stage, hormone receptor 
status, and the most important prognostic factor, axillary 
lymph node status, we found no difference between women 
with and those without a history of pHPT. Remarkably, 
none of the cases had Stage III or IV disease. Breast cancer-
specific survival was the same in the two groups.
Our study design has some limitations. Data on the 
prognostic factor, and predictive factor for trastuzumab therapy, 
Table  1  Age  distribution  of  women  with  primary  hyper-
parathyroidism and breast cancer (cases) and women with breast 
cancer only (controls)
Age group (years) Cases  
(n = 71)
Controls   
(n = 338)
(n) (n)
0–49 2 10
50–54 5 24
55–59 8 34
60–64 9 43
65–69 11 54
70–74 9 41
75–79 16 77
80+ 11 55
Note: Mean age at breast cancer diagnosis (year ± standard deviation) 69 ± 11, 
95% confidence interval 68–70.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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HER-2/neu, were incomplete, and there were no data on the 
cell proliferation marker, Ki-67. Elston–Ellis tumor grade 
could not be properly analyzed due to too many missing data, 
particularly in the earlier periods when the grade was not 
registered prospectively. Risk factors for breast cancer and 
data on calcium and vitamin D levels were not available in the 
registries.
We cannot exclude the presence of pHPT in the control 
group but, because the prevalence of pHPT in the population 
is low, it may affect only isolated cases.5
Our study design does not allow for comparisons between 
different treatment modalities, because the registry does not 
contain such data. However, the bias induced by differences 
in treatment strategy is likely to have been negligible, because 
there was near to complete compliance with regional/national 
treatment guidelines, and also by matching of five controls 
per case from the same region.
The strengths of the study are that the registers used are well 
validated and that two important prognostic factors, ie, tumor 
size and lymphatic involvement, were included.8,9 The risk of 
confounding by diagnosis was minimized by excluding all cases 
with a breast cancer diagnosis before the diagnosis of pHPT.
The coexistence of pHPT and breast cancer, recognized in 
several case reports and confirmed in large population studies, 
has given rise to much speculation concerning possible etiologic 
links.1,3,6,7 It remains to be elucidated whether the association 
between pHPT and breast cancer is due to predisposing genetic 
or environmental risk factors. Abnormalities in calcium 
metabolism have been associated with breast cancer risk, but the 
results reported from different studies have not been consistent. 
Although higher serum calcium levels have been reported 
from breast cancer cohorts, no correlation was found between 
calcium level and tumor stage.7,10,11 A causal relationship 
between hypercalcemia and malignancy seems unlikely, 
given that the risk of breast cancer remains unchanged at least 
15 years after parathyroid adenomectomy.3 Vitamin D may be 
a key factor, and there is evidence of potential links between 
vitamin D deficiency and the development and prognosis 
of breast cancer, as well as aggravated clinical presentation 
of pHPT and increased parathyroid tumor growth.12–16 A 
modestly reduced incidence of breast cancer associated with a 
higher intake of vitamin D was reported from a meta-analysis 
of observational studies.17 The results from a randomized 
clinical trial of calcium and vitamin D supplementation versus 
placebo among postmenopausal women for a mean of seven 
years showed no detectable effect on breast cancer risk.18 
However, the supplementation dose was rather low (1000 mg 
of elemental calcium with 400 IU vitamin D3 daily), additional 
use of calcium and vitamin D supplements was allowed, and 
the discontinuation rate was quite high. Comparing data 
on vitamin D levels from different observational studies is 
complicated by differences in definitions and diagnostic 
methods.19 Furthermore, many factors may interfere with the 
interpretation of vitamin D status, such as age, body mass index, 
liver and kidney function, chronic illness, and sun exposure.19,20 
Overweight is another reported risk factor that has been coupled 
with increased risk of postmenopausal breast cancer, pHPT, 
and vitamin D deficiency.11,21–23
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Figure  1  Kaplan–Meier  plots  of  breast  cancer-specific  survival  in  women  with 
phPT + breast cancer (cases) and women with breast cancer only (controls).
Table  2  Tumor  characteristics  in  women  with  phPT+breast 
cancer (cases) and women with breast cancer only (controls)
Cases 
(n = 71)
Controls 
(n = 338)
P-value
Tumor size (mm ± SD) 18 ± 10 20 ± 14 0.27
Missing 4 29
Axillary lymph node status
Negative 35 (59%) 176 (65%)
1–3 positive nodes 11 (19%) 63 (23%)
$4 positive nodes 13 (22%) 32 (12%) 0.11
Missing 12 (17%) 67 (20%)
Tumor stage
i (T1 + N0) 29 (46%) 149 (51%)
iia (T1 + N1 or T2 + N0) 25 (40%) 77 (27%)
iib (T2 + N1 or T3 + N0) 9 (14%) 49 (17%)
iii (T3 + N1 or T4) 0 (0%) 4 (1%)
iV (M1) 0 (0%) 11 (4%) 0.13c
Undefined 8 (11%) 48 (14%)
Hormone receptor status
Positivea 46 (88%) 217 (84%)
Negativeb 6 (12%) 42 (16%) 0.38
Missing 19 (27%) 79 (23%)
Notes: aEr-positive, P-positive or -negative according to local laboratory and clinical 
standards. bEr- and Pr-negative. cExact Pearson Chi-square testClinical Epidemiology
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There has also been speculation about other factors, 
such as genetic predisposition, that may influence vitamin D 
levels. Familial accumulation of hyperparathyroidism and 
breast cancer, as well as isolated cases with high penetrance 
cancer susceptibility genes, have been reported.24,25 Hitherto, 
exposure to ionizing radiation is the only established risk 
factor with a confirmed dose-response relationship for both 
parathyroid adenoma and breast cancer.26,27
Conclusion
In this study, women diagnosed with breast cancer and having 
an earlier history of pHPT had the same tumor risk factors and 
the same breast cancer-specific survival as women with breast 
cancer and no previous history of hyperparathyroidism.
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